Literature DB >> 26504095

Use of enoximone in management of anaphylaxis complicated by labetalol use.

Sophie Hayhoe1, Vilas Navapurkar1, Andrew Conway Morris2.   

Abstract

A 42-year-old woman with end-stage renal failure was admitted to the intensive care unit following resuscitation from a pulseless electrical activity cardiac arrest after intravenous piperacillin/tazobactam. Persistent bradycardia and hypotension, unresponsive to epinephrine and norepinephrine, were suspected to have been exacerbated by chronic labetalol therapy for resistant arterial hypertension. As an alternative, the non-adrenergic inotrope, enoximone, was started. This, combined with thrombolysis for possible pulmonary embolism, heralded significant haemodynamic improvement, allowing weaning from inotropic support. A clear CT pulmonary angiogram 2 days post-arrest and significantly raised mast cell tryptase levels confirmed anaphylaxis rather than pulmonary embolism as the precipitating cause. We believe this to be the first case report of phosphodiesterase-III inhibitor use in the management of anaphylaxis complicated by α/β-blockade, and discuss the mechanism behind this effect and comparison with the more commonly reported use of glucagon. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26504095      PMCID: PMC4636698          DOI: 10.1136/bcr-2015-212432

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Treatment of resistant hypertension.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  J Hypertens       Date:  2010-11       Impact factor: 4.844

2.  The pivotal role of vasopressin in refractory anaphylactic shock.

Authors:  Claudia Schummer; Melanie Wirsing; Wolfram Schummer
Journal:  Anesth Analg       Date:  2008-08       Impact factor: 5.108

Review 3.  High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning.

Authors:  Kristin M Engebretsen; Kathleen M Kaczmarek; Jenifer Morgan; Joel S Holger
Journal:  Clin Toxicol (Phila)       Date:  2011-04       Impact factor: 4.467

Review 4.  Diagnostic value of tryptase in anaphylaxis and mastocytosis.

Authors:  Lawrence B Schwartz
Journal:  Immunol Allergy Clin North Am       Date:  2006-08       Impact factor: 3.479

5.  Hypersensitivity reactions of the heart: reduction of anaphylactic crisis by theophylline or glucagon.

Authors:  R Levi
Journal:  Bull N Y Acad Med       Date:  1971-10

6.  Comparison of the anti-anaphylactic effects of milrinone, sulmazole and theophylline in the rat.

Authors:  M J Post; J D te Biesebeek; J Wemer; H H van Rooij; A J Porsius
Journal:  Int Arch Allergy Appl Immunol       Date:  1989

7.  Effects of β-adrenoceptor antagonists on anaphylactic hypotension in conscious rats.

Authors:  Wei Zhang; Toshishige Shibamoto; Yasutaka Kurata; Hiroyuki Kohno
Journal:  Eur J Pharmacol       Date:  2010-10-17       Impact factor: 4.432

8.  Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States.

Authors:  Robert A Wood; Carlos A Camargo; Philip Lieberman; Hugh A Sampson; Lawrence B Schwartz; Myron Zitt; Charlotte Collins; Michael Tringale; Marilyn Wilkinson; John Boyle; F Estelle R Simons
Journal:  J Allergy Clin Immunol       Date:  2013-10-18       Impact factor: 10.793

9.  Role of cAMP-dependent protein kinase in cAMP-mediated vasodilation.

Authors:  J Haynes; J Robinson; L Saunders; A E Taylor; S J Strada
Journal:  Am J Physiol       Date:  1992-02

10.  Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012.

Authors:  Paul J Turner; M Hazel Gowland; Vibha Sharma; Despo Ierodiakonou; Nigel Harper; Tomaz Garcez; Richard Pumphrey; Robert J Boyle
Journal:  J Allergy Clin Immunol       Date:  2014-11-25       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.